Research progress on the application of botulinum toxin type A in the treatment of myogenous temporomandibular disorders

Research progress on the application of botulinum toxin type A in the treatment of myogenous temporomandibular disorders

Blog Article

Myogenous temporomandibular disorder (M-TMD) is one of the main subtypes of Spanners temporomandibular disorder (TMD) and typically manifests as masticatory myofascial pain; the incidence of TMD has been increasing annually in recent years.Botulinum toxin type A (BTX-A) is a potent neurotoxin produced by Clostridium botulinum.BTX-A inhibits the release of acetylcholine from the presynaptic membrane, thereby blocking neuromuscular junction signaling.The noncosmetic application of BTX-A in the oral and maxillofacial regions is a prominent research topic.In recent years, an increasing number of studies have focused on the application of BTX-A in the treatment of M-TMD.

The results of a literature review revealed that an appropriate Medium Rug dose (10-50 U unilaterally) of BTX-A administered in a single injection into the masticatory muscles can effectively treat myalgia over a period of 3-6 months.Common adverse effects, such as masticatory weakness and facial paralysis, are transient and can be avoided by standardized injection techniques.However, there is a lack of standardized guidelines for injection techniques in clinical practice.